{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113963","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.090774+00:00","generated_at":"2026-05-30T16:41:10.685974+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kezar receives unsolicited $1.10/share acquisition proposal from Concentra Biosciences","bullets":["Concentra offers $1.10 per share plus a contingent value right for 80% of net proceeds from out-licensing or disposition of Kezar's programs.","Tang Capital Management, which beneficially owns ~9.9% of Kezar, is Concentra's controlling stockholder.","Kezar's Board will evaluate the non-binding proposal to determine the best course for stockholders; no immediate action required."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113963","json":"https://secwatch.observer/filing/0000950170-24-113963.json","markdown":"https://secwatch.observer/filing/0000950170-24-113963.md","text":"https://secwatch.observer/filing/0000950170-24-113963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/0000950170-24-113963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/kzr-20241010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:41:10.685974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}